General Administration Department of the National Medical Products Administration, Working Procedures for the Protection of Pharmaceutical Trial Data (Draft for Comments)
国家药监局综合司药品试验数据保护工作程序 (征求意见稿)
NMPA details procedures for apply for pharma data protection / Issued: 2025-03-19
Issued: March 19, 2025
Main contents: The Center for Drug Evaluation (the “DEC”) of the National Medical Products Administration (the “NMPA”) is responsible for specifically carrying out the data protection work under the guidance of the NMPA.
When accepting an application for marketing authorization for a chemical drug or biologic, the data protection application submitted by the pharmaceutical registration applicant (the “Applicant”) shall be reviewed simultaneously.
This premium content is reserved for
China Law & Practice Subscribers.
A Premium Subscription Provides:
- A database of over 3,000 essential documents including key PRC legislation translated into English
- A choice of newsletters to alert you to changes affecting your business including sector specific updates
- Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
Already a subscriber? Log In Now
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]